Table 4.
Treatment of Older AML patients ≥ 60 years of age.64
| Study group | Regimen | Patients | CR (%) | Early death (%) (within 30 days) |
|---|---|---|---|---|
| AMLCG | TAD9 induction and consolidation +/− maintenance | 511 | 51 | 27–34 |
| BMRC | DAT induction and consolidation | 636 | 46–48 | 30–52 |
| CALGB | Standard or intensified 7 + 3 +/− maintenance | 556 | 41–47 | 31–54 |
| SECSG | Idarubicin vs. daunorubicin + cytarabine | 111 | 53 | 20 |
| EORTC/LCG HOVON | Mitoxantrone vs. daunorubicin +/− LDAC3 maintenance | 489 | 38–47 | 6–15 |
| MDAC | Cytarabine-based intensive induction | 430 | 45 | 36 |
| Clofarabine | Clofarabine monotherapy | 112 | 38 | 10 |
| Emory | Modified HiDAC induction/consolidation | 59 | 69 | 10 |
Abbreviations: AMLCG, AML Cooperative Group; BMRC, Behavioral Medicine Research Center; CALGB, Cancer and Leukemia Group B; SECSG, Southeastern Cancer Study Group; EORTC, European Organisation for Research and Treatment of Cancer; HOVON, Hemato Oncology Foundation for Adults in the Netherlands; MDAC, MD Anderson Cancer Center.